Renaissance Technologies
KTTA icon

Renaissance Technologies’s Pasithea Therapeutics KTTA Stock Holding History

Renaissance Technologies’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8K Sell
65,600
-27,799
-30% -$19.1K ﹤0.01% 3071
2026
Q1 		$69.3K Buy
+93,399
New +$78.1K ﹤0.01% 3074
2025
Q4 		– Sell
-30,700
Closed -$22.5K – 3522
2025
Q3 		$22.5K Buy
+30,700
New +$22.4K ﹤0.01% 3416
2024
Q1 		– Sell
-1,625
Closed -$12K – 3907
2023
Q4 		$12K Buy
1,625
+82
+5% +$608 ﹤0.01% 3626
2023
Q3 		$15K Sell
1,543
-193
-11% -$2.11K ﹤0.01% 3554
2023
Q2 		$17K Buy
1,736
+186
+12% +$1.5K ﹤0.01% 3791
2023
Q1 		$12K Buy
+1,550
New +$17.5K ﹤0.01% 3873

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Renaissance Technologies's KTTA Position: Q2 2026 in Review

Renaissance Technologies reduced its Pasithea Therapeutics (KTTA) stake by 30% in Q2 2026, selling an estimated $19.1K and leaving 65,600 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Renaissance Technologies first reported a position in KTTA in Q1 2023 and has held it in 7 quarters since. The position peaked at $69.3K in Q1 2026. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Renaissance Technologies held 65,600 shares of Pasithea Therapeutics worth $33.8K as of Q2 2026.
  • Renaissance Technologies sold 27,799 Pasithea Therapeutics shares in Q2 2026, an estimated $19.1K.
  • Pasithea Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3071 holding.
  • Renaissance Technologies first reported a position in Pasithea Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • Renaissance Technologies's Pasithea Therapeutics position peaked at $69.3K in Q1 2026.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.